AUTL Stock Overview
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer.
Autolus Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.26|
|52 Week High||US$12.23|
|52 Week Low||US$4.60|
|1 Month Change||11.79%|
|3 Month Change||-7.81%|
|1 Year Change||-34.86%|
|3 Year Change||-83.96%|
|5 Year Change||n/a|
|Change since IPO||-74.96%|
Recent News & Updates
Autolus: Developing Better CAR-T In Refractory ALL
AUTL is a UK-based developer of CAR-T. It claims a better tax profile than Tecartus in adult r/r ALL. Price is currently depressed.
|AUTL||US Biotechs||US Market|
Return vs Industry: AUTL underperformed the US Biotechs industry which returned 7.3% over the past year.
Return vs Market: AUTL underperformed the US Market which returned 24.7% over the past year.
|AUTL Average Weekly Movement||10.6%|
|Biotechs Industry Average Movement||8.6%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.2%|
Stable Share Price: AUTL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: AUTL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics Fundamentals Summary
|AUTL fundamental statistics|
Is AUTL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AUTL income statement (TTM)|
|Cost of Revenue||US$133.88m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.97|
|Net Profit Margin||-5,610.45%|
How did AUTL perform over the long term?See historical performance and comparison
Is Autolus Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AUTL ($6.41) is trading below our estimate of fair value ($69.54)
Significantly Below Fair Value: AUTL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AUTL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AUTL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AUTL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AUTL is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (2.9x).
How is Autolus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AUTL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AUTL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AUTL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AUTL's revenue (74.6% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: AUTL's revenue (74.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AUTL is forecast to be unprofitable in 3 years.
How has Autolus Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AUTL is currently unprofitable.
Growing Profit Margin: AUTL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AUTL is unprofitable, and losses have increased over the past 5 years at a rate of 38.2% per year.
Accelerating Growth: Unable to compare AUTL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AUTL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: AUTL has a negative Return on Equity (-58.55%), as it is currently unprofitable.
How is Autolus Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: AUTL's short term assets ($237.7M) exceed its short term liabilities ($34.6M).
Long Term Liabilities: AUTL's short term assets ($237.7M) exceed its long term liabilities ($17.3M).
Debt to Equity History and Analysis
Debt Level: AUTL is debt free.
Reducing Debt: AUTL has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AUTL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AUTL has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 31.5% each year.
What is Autolus Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AUTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AUTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AUTL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AUTL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AUTL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Itin (57 yo)
Dr. Christian Martin Itin, also known as Chris, Ph D., has been the Chief Executive Officer of Autolus Therapeutics Plc. (Former Name: Autolus Limited) since March 3, 2016.Dr. Itin has been Director of Au...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD4.26M) is above average for companies of similar size in the US market ($USD1.69M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
Experienced Management: AUTL's management team is considered experienced (3.4 years average tenure).
Experienced Board: AUTL's board of directors are considered experienced (4.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.4%.
Autolus Therapeutics plc's employee growth, exchange listings and data sources
- Name: Autolus Therapeutics plc
- Ticker: AUTL
- Exchange: NasdaqGS
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$456.473m
- Shares outstanding: 72.92m
- Website: https://www.autolus.com
Number of Employees
- Autolus Therapeutics plc
- Forest House
- 58 Wood Lane
- Greater London
- W12 7RZ
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/26 23:02|
|End of Day Share Price||2021/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.